Stock Screener App

無料 -

インストール

0.7748

0.67% -0.0052

Estrella Immunopharma Inc (ESLA)

概要ニュース株価時系列ディスカッション予測

Estrella Immunopharma Inc (ESLA) 最新ニュース

Estrella Immunopharma Inc (ESLA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Estrella Immunopharma Inc (ESLA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Estrella Immunopharma Inc (ESLA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Estrella Immunopharma Inc (ESLA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Estrella Immunopharma Inc (ESLA) Balance Sheet - TradingKey

Estrella Immunopharma Inc (ESLA) Cash Flow - TradingKey

Estrella Immunopharma Inc (ESLA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

ESLA|Estrella Immunopharma Inc|Price:0.750|Chg%:-0.030 - TradingKey

TradingKey - TradingKey

Estrella Immunopharma Inc (ESLA) Valuation: PE, PB & Fair Value Analysis - TradingKey

Estrella Immunopharma Inc (ESLA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

ESLA|Estrella Immunopharma Inc|Price:0.780| - TradingKey

Estrella Immunopharma Inc (ESLA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Estrella Immunopharma Inc (ESLA) Institutional Confidence - TradingKey

Estrella doses first patient in EB103 trial expansion phase - Investing.com

Estrella doses first patient in EB103 trial expansion phase By Investing.com - Investing.com Canada

Estrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkin’s Lymphoma - Yahoo Finance

Price to sales forward of Estrella Immunopharma, Inc. – NASDAQ:ESLAW - TradingView

Enterprise value to EBITDA forward of Estrella Immunopharma, Inc. – NASDAQ:ESLAW - TradingView

Enterprise value to EBIT forward of Estrella Immunopharma, Inc. – NASDAQ:ESLAW - TradingView

Estrella Immunopharma, Inc. (ESLA) stock price, news, quote and history - Yahoo Finance UK

Enterprise value to revenue forward of Estrella Immunopharma, Inc. – NASDAQ:ESLAW - TradingView

Price to earnings forward of Estrella Immunopharma, Inc. – NASDAQ:ESLAW - TradingView

Enterprise value to revenue forward of Estrella Immunopharma, Inc. – NASDAQ:ESLA - TradingView

Number of shareholders of Estrella Immunopharma, Inc. – NASDAQ:ESLA - TradingView

Price to sales forward of Estrella Immunopharma, Inc. – NASDAQ:ESLA - TradingView

Estrella Immunopharma Warrant (ESLAW) Holds Steady at $0.10 Amid Low VolatilityCalendar Spread Trade - dars.gov.et

Investigation launched into Estrella Immunophar... - Pluang

AGIG: Abbott Cooper PLLC Announces Investigation on Behalf of Abundia Global Impact Group, Inc. (Formerly Houston American Energy Corp.) Stockholders - GlobeNewswire Inc.

ESLA: Abbott Cooper PLLC Announces Investigation on Behalf of Estrella Immunopharma, Inc. Stockholders - GlobeNewswire

ESLA: Abbott Cooper PLLC Announces Investigation on Behalf of Estrella Immunopharma, Inc. ... - Caledonian Record

12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga

ESLA Q2 2026 Earnings: Wider-than-Expected Loss Triggers Stock DeclineEarnings Cycle Report - dars.gov.et

Tranche Update on Estrella Immunopharma, Inc.'s Equity Buyback Plan announced on January 30, 2024. - marketscreener.com

Estrella Immunopharma, Inc. (ESLA) 8-K Filing: Shareholder Vote Results & Company Details – June 2026 - Minichart

Estrella Immunopharma Shareholders Ratify 2026 Auditor Appointment - TipRanks

Estrella Immunopharma (ESLA) investors back 2026 auditor at virtual annual meeting - Stock Titan

Enterprise value to EBITDA forward of Estrella Immunopharma, Inc. – BOATS:ESLAW - TradingView

Price to earnings forward of Estrella Immunopharma, Inc. – BOATS:ESLAW - TradingView

Estrella Immunopharma Warrants (ESLAW) Edge Lower Amid Thin TradingRisk Parity Rebalance - dars.gov.et

Estrella Immunopharma, Inc.(NasdaqCM:ESLA) added to Russell Microcap Value Benchmark Index - marketscreener.com

Estrella Immunopharma, Inc.(NasdaqCM: ESLA) added to Russell 3000E Value Benchmark - marketscreener.com

Estrella Immunopharma Inc. (ESLA) Q1 2026 Earnings: Wider-than-Expected Loss Drives Stock Volatility - dars.gov.et

Estrella Immunopharma, Inc. Actuals & Estimates (NASDAQ:ESLA) - TradingView

ESLA Q1 2026 Earnings: EPS Misses Estimates by 90.6% Amid Pre-Revenue PhaseSlow Growth Warning - dars.gov.et

Estrella Immunopharma Inc. (ESLA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Estrella Immunopharma Inc (ESLAW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Estrella Immunopharma Inc (ESLAW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Estrella Immunopharma Inc - TradingKey

Estrella Immunopharma Inc (ESLAW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Estrella Immunopharma Inc (ESLAW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Estrella Immunopharma Inc (ESLAW) Institutional Confidence - TradingKey

Estrella Immunopharma Inc (ESLAW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Estrella Immunopharma Inc (ESLAW) Valuation: PE, PB & Fair Value Analysis - TradingKey

Estrella Immunopharma Inc. (ESLA) Q1 2026 Earnings: EPS Misses Estimates Amid Pre-Revenue R&D FocusGuidance Revision Trend - dars.gov.et

Estrella Immunopharma Inc. (ESLA) Q1 2026 Earnings: Miss on EPS as Pre-Revenue Biotech Navigates Clinical DevelopmentEarnings Surprise Stocks - newsline.com

Estrella Immunopharma (ESLA) Edges Higher Amid Broader Biotech SentimentWyckoff Accumulation - newsline.com

ESLAW Warrants Slide 13% as Support at $0.10 Faces Critical TestStop Hunt - newsline.com

BNTX

$91.09

1.97%

INCY

$118.87

1.02%

ROIV

$34.72

0.83%

RPRX

$58.73

0.17%

ONC

$325.90

0.00%

ALNY

$278.40

2.44%

Yahooで開く | Google で開く | Finviz で開く | マーケットウォッチで開く | エドガーでオープン | ロイターで開く